Clinical and Economic Outcomes of a Pharmacogenomics-enriched Comprehensive Medication Management Program in a Self-insured Employee Population
Authors:
- Maren FragalaMFMaren Fragala
- Murray KeoghMKMurray Keogh
- Steven GoldbergSGSteven Goldberg
- Raymond LorenzRLRaymond Lorenz
- Jeffrey ShamanJSJeffrey Shaman
Preprint
- 18 September 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
Clinical and economic outcomes from a pharmacogenomics-enriched comprehensive medication management program were evaluated over 26-months in a self-insured employee population (n=452 participants; n=1,500 controls) using propensity matched pre-post design with adjusted negative binomial and linear regression models. After adjusting for baseline covariates, program participation was associated with 39% fewer inpatient (p=0.05) and 39% fewer emergency department (p=0.002) visits, and with 21% more outpatient visits (p<0.001) in the follow-up period compared to the control group. Results show pharmacogenomics-enriched comprehensive medication management can favorably impact healthcare utilization in a self-insured employer population by reducing emergency department and inpatient visits and can offer potential for cost savings. Self-insured employers may consider implementing pharmacogenomics-enriched comprehensive medication management to improve the healthcare of their employees.Keywords
All Related Versions
- Version 1, 2023-09-18, Research Square
- Published version: The Pharmacogenomics Journal, 24 (5), 1.
This publication has 21 references indexed in Scilit:
- Primary care visits increase utilization of evidence-based preventative health measuresBMC Family Practice, 2020
- PharmacogenomicsThe Lancet, 2019
- Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy UsersJAMA Network Open, 2019
- Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic?Clinical Pharmacology & Therapeutics, 2019
- The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature DatabaseClinical Pharmacology & Therapeutics, 2017
- Economic Evaluation of Pharmacogenomic-Guided Warfarin Treatment for Elderly Croatian Atrial Fibrillation Patients with Ischemic StrokePharmacogenomics, 2015
- Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive GenotypingClinical Pharmacology & Therapeutics, 2012
- Doubly Robust Estimation of Causal EffectsAmerican Journal of Epidemiology, 2011
- CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research NetworkClinical Pharmacology & Therapeutics, 2011
- Pharmacogenomics — Drug Disposition, Drug Targets, and Side EffectsNew England Journal of Medicine, 2003